Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: An open-label extension study

Kim, Sun Hwa; Kim, Sin Gon; Kim, Doo Man; Woo, Jeong-Taek; Jang, Hak Chul; Chung, Choon Hee; Ko, Kyung Soo; Park, Jeong Hyun; Park, Yong Soo; Kim, Sang Jin; Choi, Dong Seop

doi:10.1016/j.diabres.2015.09.009

상세 보기

Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: An open-label extension study

Kim, Sun Hwa;
Kim, Sin Gon;
Kim, Doo Man;
Woo, Jeong-Taek;
Jang, Hak Chul;
... Choi, Dong Seop;
외 5명

Citations

WEB OF SCIENCE

33

Citations

SCOPUS

31

초록

We aimed to assess the safety and efficacy of lobeglitazone in patients with type 2 diabetes over 52 weeks through 28-week extension study. Clinical benefits in terms of glycemic and lipid control were maintained for 52 weeks. Lobeglitazone showed a favorable balance of efficacy and safety during the extension study. (C) 2015 Elsevier Ireland Ltd. All rights reserved.

키워드

Lobeglitazone; Thiazolidinediones; Clinical trial; Randomised trial; GLYCEMIC CONTROL; PARALLEL-GROUP; DOUBLE-BLIND; PIOGLITAZONE; METFORMIN; THIAZOLIDINEDIONES; TRIAL

제목: Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: An open-label extension study

저자: Kim, Sun Hwa; Kim, Sin Gon; Kim, Doo Man; Woo, Jeong-Taek; Jang, Hak Chul; Chung, Choon Hee; Ko, Kyung Soo; Park, Jeong Hyun; Park, Yong Soo; Kim, Sang Jin; Choi, Dong Seop

DOI: 10.1016/j.diabres.2015.09.009

발행일: 2015-12

유형: Article

저널명: Diabetes Research and Clinical Practice

권: 110

호: 3

페이지: E27 ~ E30

언어: ENG

출판사: Elsevier BV

발행국가: 아일랜드

ISSN: E 1872-8227
P 0168-8227